Klertis (Sunitinib)

Sunitinib blocks several receptor tyrosine kinases such as VEGFR, PDGFR, KIT and FLT3. By inhibiting these receptors, it reduces angiogenesis—the formation of new blood vessels that feed tumors—and directly interferes with tumor cell proliferation, leading to slowed disease progression.

The specific dose and schedule of Klertis are determined by the treating physician based on the patient’s condition, weight, renal and hepatic function, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of sunitinib in pregnancy and lactation has not been established, and the product carries an unknown pregnancy category. It is generally contraindicated in pregnant women and should be avoided during breastfeeding unless the benefits outweigh the risks and a specialist advises otherwise.

To order Klertis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative to sunitinib in these indications is pazopanib, another oral tyrosine kinase inhibitor. While both target VEGFR and PDGFR, sunitinib has a broader kinase profile that includes KIT and FLT3, which may offer efficacy advantages in certain GIST and neuroendocrine tumors, but the side‑effect spectrum differs and should be considered when selecting therapy.

Klertis tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct light, and keep out of reach of children. Do not refrigerate or freeze the tablets.

Klertis is taken orally as a tablet, usually with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s guidance regarding timing relative to meals to minimize gastrointestinal discomfort.

Serious risks include severe hypertension, cardiac dysfunction such as reduced left‑ventricular ejection fraction or heart failure, and significant liver injury indicated by marked enzyme elevations or hepatitis. Patients should report symptoms like persistent high blood pressure, shortness of breath, chest pain, jaundice or unusual fatigue to their healthcare provider promptly.

Klertis should be avoided in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to sunitinib or any tablet excipients. It is also contraindicated during pregnancy and is not recommended for breastfeeding women unless a specialist determines the benefits outweigh the risks.